Composés chimiques

Pyrrolo [2, 3, b] pyridine derivatives useful as raf kinase inhibitors

Abstract

The present invention provides ethyl pyrazole compounds of formula (I): compositions containing the same, as well as processes for the preparation and their use as pharmaceutical agents.
La présente invention concerne des composés de pyrazole d'éthyle, les compositions contenant ces composés, leurs procédés de préparation et leur utilisation comme agents pharmaceutiques.

Claims

Description

Topics

Download Full PDF Version (Non-Commercial Use)

Patent Citations (1)

    Publication numberPublication dateAssigneeTitle
    FR-2878849-A1June 09, 2006Aventis Pharma SaIndoles substitues, compositions les contenant, procede de fabrication et utilisation

NO-Patent Citations (2)

    Title
    BRANA M F ET AL: "Pyrazolo[3,4-c]pyridazines as novel and selective inhibitors of cyclin-dependent kinases" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 48, no. 22, November 2005 (2005-11), pages 6843-6854, XP002379976 ISSN: 0022-2623
    N. KEEN ET AL.: "Aurora-kinase inhibitors as anticancer agents" NATURE CANCER REVIEWS, vol. 4, 2004, pages 927-936, XP002449736

Cited By (18)

    Publication numberPublication dateAssigneeTitle
    US-8691807-B2April 08, 2014Incyte CorporationAzetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
    US-8933085-B2January 13, 2015Incyte CorporationCyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
    US-8933086-B2January 13, 2015Incyte CorporationHeteroaryl substituted pyrrolo[2,3-B]pyridines and pyrrolo[2,3-B]pyrimidines as Janus kinase inhibitors
    US-8946245-B2February 03, 2015Incyte CorporationHeteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
    US-8987443-B2March 24, 2015Incyte CorporationProcesses and intermediates for making a JAK inhibitor
    US-9023840-B2May 05, 2015Incyte CorporationAzetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
    US-9034884-B2May 19, 2015Incyte CorporationHeterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
    US-9193733-B2November 24, 2015Incyte Holdings Corporation, Incyte CorporationPiperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
    US-9206187-B2December 08, 2015Incyte Holdings Corporation, Incyte CorporationHeteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase
    US-9216984-B2December 22, 2015Incyte Corporation, Incyte Holdings Corporation3-[4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl]octane—or heptane-nitrile as JAK inhibitors
    US-9221845-B2December 29, 2015Incyte Holdings Corporation, Incyte CorporationProcesses and intermediates for making a JAK inhibitor
    US-9249145-B2February 02, 2016Incyte Holdings Corporation, Incyte CorporationHeterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
    US-9334274-B2May 10, 2016Incyte Holdings Corporation, Incyte CorporationN-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
    US-9359358-B2June 07, 2016Incyte Holdings Corporation, Incyte CorporationCyclohexyl azetidine derivatives as JAK inhibitors
    US-9464088-B2October 11, 2016Incyte Holdings Corporation, Incyte CorporationPiperidin-4-yl azetidine derivatives as JAK1 inhibitors
    US-9487521-B2November 08, 2016Incyte Holdings Corporation, Incyte CorporationProcesses and intermediates for making a JAK inhibitor
    US-9498467-B2November 22, 2016Incyte CorporationTreatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
    US-9814722-B2November 14, 2017Incyte Holdings Corporation, Incyte CorporationHeteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors